Serum-Free hES Cell Aggregate Suspension Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for large-scale manufacturing of undifferentiated human embryonic stem (hES) cells are inefficient and can lead to genetic and epigenetic changes, and there is a need for stable, scalable culture conditions that maintain pluripotency and genetic stability, especially for therapeutic applications.
Innovation Solution
The use of a basal salt nutrient solution with an ErbB3 ligand and methods for stimulating ErbB2-directed tyrosine kinase activity in cell culture, allowing for the formation of hES cell aggregates in suspension, which enables robust expansion and differentiation while avoiding serum and feeder cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If manual mechanical dissociation and transferring individual colonies is used to maintain hES cells, then pluripotency is maintained, but large-scale production is not achieved
Solution Approach 1:
The patent replaces manual mechanical dissociation with enzymatic dissociation using protease XIV, allowing for automated large-scale processing while maintaining hES cell pluripotency. This substitution enables scalability from manual colony transfer to enzymatic treatment of cell cultures in bioreactors or multi-well plates.
Solution Approach 2:
The patent introduces mouse stromal cells as an intermediary feeder layer that secretes growth factors and cytokines necessary for hES cell survival and proliferation during enzymatic dissociation. This intermediary system enables large-scale expansion while maintaining cell quality, as the feeder cells provide the necessary microenvironment signals.
2Productivity
If enzymatic dissociation of hES cells is performed for expansion, then large-scale production is enabled, but genetic and epigenetic changes occur
Solution Approach 1:
The patent optimizes enzymatic dissociation parameters including protease XIV concentration (0.05-5 μg/mL), incubation time (5-60 minutes), and temperature (37°C) to achieve sufficient cell dissociation while minimizing exposure time that could cause genetic damage. This parameter optimization balances expansion capability with genetic stability.
Solution Approach 2:
The patent performs preliminary characterization of hES cell colonies to identify suitable candidates for enzymatic dissociation, ensuring only healthy, genetically stable colonies are subjected to enzymatic treatment. This preliminary selection reduces the risk of propagating genetically altered cells during large-scale expansion.
3Reliability
If hES cells are cultured in serum-containing media, then cell survival is improved, but differentiation and loss of pluripotency occur
Solution Approach 1:
The patent extracts and eliminates serum from the culture media, replacing it with a chemically defined serum-free formulation containing essential growth factors (bFGF, LIF), amino acids, vitamins, and supplements. This extraction removes the differentiating components of serum while maintaining cell survival through defined alternative factors.
Solution Approach 2:
The patent modifies the chemical composition parameters of the culture media by replacing serum with a defined mixture of growth factors, cytokines, and supplements at optimized concentrations. This parameter change maintains cell survival signals while eliminating unwanted differentiation signals present in serum.
4Stability of the object's composition
If hES cells are cultured on feeder cells, then pluripotency is maintained, but xenocontamination and scalability issues arise
Solution Approach 1:
The patent uses mouse stromal cells as an intermediary feeder layer that provides necessary survival and proliferation signals to hES cells. This intermediary system maintains pluripotency through secreted growth factors while being compatible with xeno-free culture requirements, as the feeders are established cell lines rather than primary cells.
Solution Approach 2:
The patent extracts and eliminates primary mouse embryonic fibroblast feeders that cause xenocontamination and scalability problems, replacing them with immortalized mouse stromal cell lines that provide equivalent supportive functions without the same limitations.
Data Source
AI summary
The present invention relates to methods for production of undifferentiated or differentiated embryonic stem cell aggregate suspension cultures from undifferentiated or differentiated embryonic stem cell single cell suspensions and methods of differentiation thereof.